Ex vivo expansion of TIL with the IL-2-based systems greatly reduces CD27 and CD28 expression, resulting in reduced persistence and subsequent limited anti-tumor activity in vivo[24-27,39]. This evidence concerns the gene CD27 and neoplasm.